A detailed history of Geode Capital Management, LLC transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,084,727 shares of PYXS stock, worth $1.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,084,727
Previous 1,027,711 5.55%
Holding current value
$1.83 Million
Previous $3.4 Million 17.02%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.83 - $3.94 $161,355 - $224,643
57,016 Added 5.55%
1,084,727 $3.98 Million
Q2 2024

Aug 09, 2024

BUY
$3.06 - $5.58 $2.1 Million - $3.84 Million
687,590 Added 202.16%
1,027,711 $3.4 Million
Q1 2024

May 13, 2024

BUY
$2.03 - $6.59 $64,716 - $210,089
31,880 Added 10.34%
340,121 $1.45 Million
Q4 2023

Feb 13, 2024

BUY
$1.4 - $2.09 $27,918 - $41,678
19,942 Added 6.92%
308,241 $554,000
Q3 2023

Nov 13, 2023

BUY
$1.6 - $2.78 $72,819 - $126,523
45,512 Added 18.75%
288,299 $573,000
Q2 2023

Aug 11, 2023

BUY
$2.46 - $4.07 $8,452 - $13,984
3,436 Added 1.44%
242,787 $621,000
Q1 2023

May 15, 2023

BUY
$1.38 - $6.0 $48,875 - $212,502
35,417 Added 17.37%
239,351 $959,000
Q4 2022

Feb 13, 2023

BUY
$1.14 - $2.0 $17,228 - $30,226
15,113 Added 8.0%
203,934 $273,000
Q3 2022

Nov 14, 2022

BUY
$1.88 - $3.03 $148,471 - $239,291
78,974 Added 71.89%
188,821 $371,000
Q2 2022

Aug 12, 2022

SELL
$2.02 - $4.53 $171,154 - $383,826
-84,730 Reduced 43.55%
109,847 $261,000
Q1 2022

May 13, 2022

BUY
$4.04 - $11.43 $52,944 - $149,790
13,105 Added 7.22%
194,577 $786,000
Q4 2021

Feb 11, 2022

BUY
$8.39 - $13.64 $1.52 Million - $2.48 Million
181,472 New
181,472 $1.99 Million

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $59.3M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.